Publisher: Bentham Science Publishers
E-ISSN: 1875-5453|17|5|469-477
ISSN: 1389-2002
Source: Current Drug Metabolism, Vol.17, Iss.5, 2016-06, pp. : 469-477
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Background: Over the decade, miRNAs are the most important molecules for the biopharmaceutical industry due to their relation with several human diseases. Presently, the phase-II clinical trial has been initiated for the first miRNA-based therapeutics (“Miravirsen”) to treat HCV infection. It has been expected that many more miRNA-based therapeutics will enter the clinical trials. Therefore, it is important to develop different kinds of novel delivery systems with better efficacy and more efficiency, but fewer side effects.Methods: We have undertaken a structured search of bibliographic databases for peer-reviewed research literature to solve our review question. Literature survey was performed widely to write this review article.Results: In this review, we have discussed the various types of miRNA delivery systems such as viral vectors, lipid-based systems, nanocarriers, and LNA-customized DNA delivery without any delivery-mediated agent. Current status, technical support, and the future challenges for miRNA-based delivery are also discussed.Conclusion: Recent development and understanding of miRNA had shown the therapeutic potentiality of miRNA.
Related content
Stent-based drug-delivery systems: current challenges and future trends
Therapeutic Delivery, Vol. 4, Iss. 9, 2013-09 ,pp. :
Delivery of Therapeutic Proteins: Challenges and Strategies
Current Drug Targets, Vol. 17, Iss. 10, 2016-08 ,pp. :
Vaccine Delivery - Current Trends and Future
Current Drug Delivery, Vol. 3, Iss. 2, 2006-04 ,pp. :